Cancer is a dynamic process that proceeds through the accumulation of genomic alterations. Large sequencing projects have illuminated the complex static landscapes of alterations across a large number of tumors. However, these studies have failed to address the dynamic nature of cancers. Understanding how tumors are shaped by selective pressures bears implications in therapies and prognoses. To address this issue we propose PITCH (Parsimony Inference of Tumor Clone Heterogeneity), a computational model that aims to uncover the evolutionary history of tumors using high throughput genomic data from cross-sectional studies. PITCH identifies traces of older clones and reconstructs possible histories of lesions. By combining the data from different patients, PITCH is able to capture statistically robust historical relationships between driver alterations in tumors and to represent these relationships as an evolutionary network. We will calibrate the approach in a longitudinal cohort of nearly 1,500 Chronic Lymphocytic Leukemia patients spanning a period of 12 years, along with 20 Glioblastoma Multiforme samples.
We aim to extend and thus experimentally validate the approach using the large collection of Glioblastoma Multiforme and Low Grade Glioma in The Cancer Genome Atlas. We will be able to provide a robust computational approach that can be easily extended to any other tumor type where large cross-sectional data is available. Discovery of alterations associated to different phases, stages or therapeutic strategies could provide invaluable biomarkers for personalized approaches based on genomic data.

Public Health Relevance

Tumors are dynamic biological entities that evolve through the accumulation of genetic alterations. In this proposal, we aim to uncover the history of tumors through the analysis of high throughput genomic data from cross-sectional studies. This work will provide a strategy for the identification of alterations that mark the different stages of the evolution of a tumor.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Li, Jerry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Rabadan, Raul; Bhanot, Gyan; Marsilio, Sonia et al. (2018) On statistical modeling of sequencing noise in high depth data to assess tumor evolution. J Stat Phys 172:143-155
Tzoneva, Gannie; Dieck, Chelsea L; Oshima, Koichi et al. (2018) Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553:511-514
Madubata, Chioma J; Roshan-Ghias, Alireza; Chu, Timothy et al. (2017) Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. NPJ Genom Med 2:29
Lee, Jin-Ku; Wang, Jiguang; Sa, Jason K et al. (2017) Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet 49:594-599
Lasorella, Anna; Sanson, Marc; Iavarone, Antonio (2017) FGFR-TACC gene fusions in human glioma. Neuro Oncol 19:475-483
Wang, Jiguang; Cazzato, Emanuela; Ladewig, Erik et al. (2016) Clonal evolution of glioblastoma under therapy. Nat Genet 48:768-76
Yamamoto, Kenta; Wang, Jiguang; Sprinzen, Lisa et al. (2016) Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. Elife 5:
Ceccarelli, Michele; Barthel, Floris P; Malta, Tathiane M et al. (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164:550-63
Del Giudice, Ilaria; Marinelli, Marilisa; Wang, Jiguang et al. (2016) Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. Br J Haematol 172:371-383
Oshima, Koichi; Khiabanian, Hossein; da Silva-Almeida, Ana C et al. (2016) Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 113:11306-11311

Showing the most recent 10 out of 16 publications